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Background: Neuroblastoma are pediatric tumors of the sympathetic nervous system with a poor prognosis.
Apoptosis is often deregulated in cancer cells, but only a few defects in apoptotic routes have been identified in
neuroblastoma.
Methods: Here we investigated genomic aberrations affecting genes of the intrinsic apoptotic pathway
in neuroblastoma. We analyzed DNA profiling data (CGH and SNP arrays) and mRNA expression data of 31
genes of the intrinsic apoptotic pathway in a dataset of 88 neuroblastoma tumors using the R2 bioinformatic
platform (http://r2.amc.nl). BIRC6 was selected for further analysis as a tumor driving gene. Knockdown
experiments were performed using BIRC6 lentiviral shRNA and phenotype responses were analyzed by Western
blot and MTT-assays. In addition, DIABLO levels and interactions were investigated with immunofluorescence
and co-immunoprecipitation.
Results: We observed frequent gain of the BIRC6 gene on chromosome 2, which resulted in increased mRNA
expression. BIRC6 is an inhibitor of apoptosis protein (IAP), that can bind and degrade the cytoplasmic fraction
of the pro-apoptotic protein DIABLO. DIABLO mRNA expression was exceptionally high in neuroblastoma but
the protein was only detected in the mitochondria. Upon silencing of BIRC6 by shRNA, DIABLO protein levels
increased and cells went into apoptosis. Co-immunoprecipitation confirmed direct interaction between DIABLO
and BIRC6 in neuroblastoma cell lines.
Conclusion: Our findings indicate that BIRC6 may have a potential oncogenic role in neuroblastoma by
inactivating cytoplasmic DIABLO. BIRC6 inhibition may therefore provide a means for therapeutic intervention in
neuroblastoma.
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BIRC6 (also known as BRUCE or APOLLON) is a cyto-
plasmic protein with a dual role. Firstly, BIRC6 has an
anti-apoptotic function in the intrinsic apoptotic path-
way by antagonizing the pro-apoptotic DIABLO protein.
BIRC6 can bind the cytoplasmic DIABLO fraction and
induce ubiquitination and proteasomal degradation of
this protein [1,2]. BIRC6 thereby protects against the* Correspondence: j.j.molenaar@amc.uva.nl
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reproduction in any medium, provided the orpro-apoptotic function of DIABLO. DIABLO is a mito-
chondrial protein which is released into the cytoplasm
upon an apoptotic stimulus. This release is regulated by
the levels of the BH3 family proteins, which induce pore
formation in the mitochondrial membrane [3-5]. Cyto-
plasmic DIABLO can bind to the BIR domains of BIRC2
(cIAP1), BIRC3 (cIAP2) and BIRC4 (XIAP), thereby
inhibiting the anti-apoptotic function of these proteins
[6]. A second function of BIRC6 has been shown in re-
cent studies where BIRC6 was required for abscission
and membrane delivery during the midbody ring forma-
tion during cell division [7,8].
BIRC6 is highly expressed in several types of cancer.
BIRC6 over-expression in acute myeloid leukemia is
correlated with a poor outcome [9]. A genome wideLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lymphoma showed that a region of 2p including the
BIRC6 gene was gained in a few samples [10]. Addition-
ally, high BIRC6 expression in colon cancer stem cells is
associated with drug resistance [11].
Neuroblastoma are pediatric tumors that originate
from the embryonal precursor cells of the sympathetic
nervous system. High stage tumors have a poor progno-
sis with 20 to 40% overall survival [12-14]. BIRC6 is
located on chromosome 2p in the region which shows
frequent gain in neuroblastoma [12]. This region
includes both MYCN and ALK, two well characterized
oncogenes in neuroblastoma. Amplification of MYCN
occurs in 20–30% of neuroblastoma and strongly corre-
lates with a poor prognosis [12-15]. ALK was recently
found to be mutated in 6-10% of primary neuroblastoma
[16-20]. MYCN amplification and ALK mutations seem
independent of the gain of chromosome 2p [21] and
therefore other additional tumor driving genes could be
located on this frequently gained region.
The apoptotic pathway has been widely investigated in
neuroblastoma and only a few tumor driving events have
been described. TP53 is mostly intact in primary neuro-
blastoma although functional defects in the p53 pathway
have been described [22]. Caspase 8 (CASP8) is hyper-
methylated and thereby inactivated in some neuroblast-
oma resulting in an inactive extrinsic apoptotic pathway
[23]. The IAP BIRC5 (Survivin) is located on the
chromosome 17q region which is frequently gained in
neuroblastoma and high BIRC5 expression correlates
with a poor prognosis [24-26]. Also, the anti-apoptotic
mitochondrial BCL2 protein is highly expressed in
neuroblastoma. Targeted inhibitors against BIRC5 [27-32]
and BCL2 [33] are currently being tested for clinical
implementation, however, the poor prognosis of high
grade neuroblastoma makes the identification of add-
itional targets for therapeutic intervention desirable.
To identify patterns in aberrations of genes involved in
intrinsic apoptotic signaling we combined high through-
put analysis of DNA copy number and mRNA expres-
sion of these genes in a dataset of 88 neuroblastoma
tumors. We found BIRC5 and BIRC6 to be frequently
gained and CASP9 often lost. Since BIRC6 was not pre-
viously evaluated in a neuroblastoma model, we studied
the potency of BIRC6 as a potential new target for
neuroblastoma therapy. Silencing of BIRC6 induced
apoptosis and up-regulation of DIABLO. We established
BIRC6 to physically interact with DIABLO, indicating
that BIRC6 can degrade DIABLO very effectively.
Methods
Patient samples
We used a neuroblastoma tumor panel for Affymetrix
Microarray analysis containing 88 primary neuroblastomatumor samples of untreated patients of which 87 neuro-
blastoma tumor samples were also used for CGH ana-
lysis and SNP array [34]. All neuroblastoma samples
were residual material obtained during surgery for diag-
nostic purposes and immediately frozen in liquid nitro-
gen. Ethical approval of the Dutch Medical Ethical
Committee was not needed for the use of surplus mate-
rials. However, informed consent was taken from the
parents of the patients for use of this material which is
archived at the Academic Medical Center from the
University of Amsterdam. The data were deposited in
the NCBI Gene Expression Omnibus (http://www.ncbi.
nlm.nih.gov/geo/) under accession number GSE16476
[35]. Public available neuroblastoma datasets we used
were of Delattre [36] and Lastowska (geo ID: gse13136).
Public available datasets were used for comparing
neuroblastoma with normal tissues (Roth dataset, geo
ID: gse3526) and adult tumors (EXPO dataset, geo ID:
gse2109).
Affymetrix mRNA expression analysis
Total RNA of neuroblastoma tumors was extracted using
Trizol reagent (Invitrogen, Carlsbad, CA) according to
the manufacturer’s protocol. RNA concentration and
quality were determined using the RNA 6000 nano assay
on the Agilent 2100 Bioanalyzer (Agilent Technologies).
Fragmentation of cRNA, hybridization to hg-u133 plus
2.0 microarrays and scanning were performed according
to the manufacturer’s protocol (Affymetrix inc).
Array CGH analysis
High-molecular-weight DNA was isolated from tumor
tissue by a standard salt-chloroform extraction method
[37]. For reference DNA we obtained healthy tissue.
We used a custom 44 K Agilent aCGH chip, enriched
for critical regions of loss/gain for neuroblastoma
(10 kb resolution), miRNAs/T-UCRs (5 oligos/gene)
and cancer gene census genes (5 oligos/gene) (Agilent
Technologies). A total of 150 ng of tumor and refer-
ence DNA was labeled with Cy3 and Cy5, respectively
(BioPrime ArrayCGH Genomic Labeling System, Invi-
trogen). Further processing was done according to the
manufacturer’s guidelines. Features were extracted
using the feature extraction v10.1.0.0.0 software pro-
gram. Data were further analyzed using the R2 web
application (see below). Circular binary segmentation
was used for scoring the regions of gain, amplification
and deletion.
Whole-genome genotyping
Tumor DNA was extracted as previously described,
quantified with NanoDrop and the quality was deter-
mined by the Abs 260/280 and 230/260 ratio. SNP
arrays were processed for analysis of copy number
Table 1 Selected genes in the intrinsic apoptotic pathway
Gene family or category Gene (alias)
Anti-apoptotic members of BCL2 family BCL2
MCL1
BCL2L1 (BCLXL)
BCL2L2 (BCLW)
BCL2A1
BCL2L10
Pro-apoptotic members of BCL2 family BBC3 (PUMA)
BCL2L11 (BIM)
BID
PMAIP1 (NOXA)
BAD
BIK
HRK
BCL2L14
BMF
Mitochondrial permeabilization BAX
BAK1
Cytoplasmic pro-apoptotic genes DIABLO
CYCS
APAF1
Caspases, activated by mitochondrial
apoptotic pathway
CASP3
CASP6
CASP7
CASP9
IAPs NAIP
XIAP
BIRC5
BIRC6
BIRC7
Activation of mitochondrial apoptotic pathway TP53
CASP2
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quad arrays containing> 370 000/> 660 000 markers
and run on the Illumina Beadstation (Swegene Centre
for Integrative Biology, Lund University – SCIBLU, Swe-
den) according to the manufacturer’s recommendations.
Raw data were processed using Illumina’s BeadStudio
software suite (Genotyping module 3.0), producing re-
port files containing normalized intensity data and SNP
genotypes. Subsequently, log 2 Ratio and B-allele fre-
quency data were imported into the R2 web application
for detailed analysis and comparison with the CGH and
expression data.
Bioinformatics
All data were analyzed using the R2 web application,
which is publicly available at http://r2.amc.nl. The expres-
sion data were normalized with the MAS5.0 algorithm
within the GCOS program of Affymetrix Inc. Target in-
tensity was set to 100. For scoring genomic aberrations of
the 31 included genes (see below and Table 1), we consid-
ered CGH aberrant if the logfold value was more than
0.45 for gain or less than −0.45 for loss and if a breaking
point was clearly visible. We excluded whole chromosome
gains or losses. Also, the detected gains or losses had to
be confirmed by SNP array.
Cell lines
All cell lines were grown in Dulbecco Modified Eagle
Medium (DMEM), supplemented with 10% fetal calf
serum, 10 mM L-glutamine, 10 U/ml penicillin/strepto-
mycin, Non Essential Amino Acids (1x) and 10 μg/ml
streptomycin. Cells were maintained at 37°C under 5%
CO2. For primary references of these cell lines, see
Molenaar et al. [35].
Lentiviral shRNA production and transduction
Lentiviral particles were produced in HEK293T cells by
co-transfection of lentiviral vector containing the short
hairpin RNA (shRNA) with lentiviral packaging plas-
mids pMD2G, pRRE and pRSV/REV using FuGene
HD. Supernatant of the HEK293T cells was harvested
at 48 and 72 h after transfection, which was purified by
filtration and ultracentrifugation. The concentration
was determined by a p24 ELISA. Cells were plated at a
10% confluence. After 24 h cells were transduced
with lentiviral DIABLO shRNA (Sigma, ‘E8’:
TRCN0000004511 and ‘E9’: TRCN0000004512) or
BIRC6 shRNA (Sigma, ‘C7’: TRCN0000004157 and
‘C11’: TRCN0000004161) in various concentrations
(Multiplicity of infection (MOI): 1–3). SHC-002 shRNA
(non-targeting shRNA: CAACAAGATGAAGAGCAC-
CAA) was used as a negative control. Medium was
refreshed 24 h after transduction and puromycin was
added to select for transduced cells. Protein washarvested 72 h after transduction and analyzed by
Western blot.
Compounds
ABT263, a small molecule BCL2 inhibitor, was dissolved
in DMSO to a concentration of 20 mM as stock solu-
tion. A final concentration of 200 nM ABT263 was used.
For the experiment using this compound we chose
SJNB12 instead of IMR32 or SKNSH for its high expres-
sion of BCL2 and its subsequent high sensitivity to this
compound [33].
Z-Val-Asp(OMe)-Val-Ala-Asp(OMe)-FMK (ZVDVAD-
FMK, a widely used CASP2 inhibitor; R&D systems) was
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concentration of 20 μM.
Western blotting
Attached and floating cells were harvested on ice 72 h
after transduction with shRNA. Cells were lyzed with
Laemmlibuffer (20% glycerol, 4% SDS, 100 mM Tris
HCl pH 6.8 in mQ). Protein concentrations were quanti-
fied with RC-DC protein assay (Bio-Rad, Hercules,
USA). Lysates were separated on a 10% SDS-Page gel
and transferred onto a blotting membrane (Millipore,
IPFL00010). Blocking and incubation were performed in
OBB according to manufacturer’s protocol (LI-COR).
Primary antibodies used were anti-BIRC6 (Abcam,
ab19609), anti-DIABLO (Abcam, ab32023), anti-PARP
(Cell Signaling: 9542) and anti-BCL2 (Cell Signalling;
2872). Protein loading was checked by anti-β-actin
(Abcam, ab6276) or anti-α-tubulin (Sigma, T5168). The
secondary antibodies used were provided by LI-COR.
Proteins were visualized with the Odyssey bioanalyzer
(LI-COR).
In cell western
Cells were fixed with 4% paraformaldehyde for 20 min
48 h after transduction with BIRC6 shRNA. Blocking
and incubation were performed in OBB according to
manufacturer’s protocol (LI-COR). Primary antibodies
used were anti-BIRC6 (BD Biosciences, 611193) and
anti-β-actin mouse monoclonal (Abcam, ab6276). Pro-
teins were visualized with the Odyssey bioanalyzer (LI-
COR) and quantified and corrected for β-actin using the
Odyssey software.
Immunofluorescence
Cells were grown on glass slides in 6-well plates and were
fixed with 4% paraformaldehyde in PBS 48 h after trans-
duction. We used anti-DIABLO (Abcam, ab32023) as a
primary antibody, and anti-rabbit (Alexa, 11012) as a sec-
ondary antibody. Mitochondria were stained using Mito-
tracker (Invitrogen, M22426). Antibodies were dissolved
in 5% ELK in PBS/0.2% tween-20. Slides were stained
with DAPI (1:1000) in vectashield (Vector Laboratories).
Cell fractionation
Protein was harvested and fractionated using the Subcel-
lular Proteome Extraction Kit according to manufac-
turer’s protocol (Novagen, 539790). Fraction I (cytosol)
and II (membrane/organelle) were used for Western blot.
Co-immunoprecipitation
Cells were lyzed in a buffer containing 150 mM NaCl,
50 mM Hepes, 5 mM EDTA, 0.3% NP-40, 10 mM
β-glycerophosphate, 6% glycerol, protease inhibitors
(Complete mini, Roche) and Phosphatase inhibitors(5 mM NaF, 1 mM Na2VO3). The antibody used for
IP was anti-BIRC6 (Abcam, ab19609); negative controls
were anti-flag (Cell Signaling, 2368) and protein with-
out antibody. Protein-G agarose beads (Roche) and
antibody were incubated for pre-coupling overnight
after which lysates were added and incubated over-
night. Immunocomplexes were washed, heated at 95°C
for 10 min and loaded on a gel for Western blot.
Primary antibodies used were anti-BIRC6 and anti-
DIABLO (Abcam; ab32023). Blots were incubated
overnight with primary antibodies, after which a one
hour incubation step with anti-rabbit IgG (Cell Sig-
naling; 3678) was performed followed by incubation
with the secondary antibody provided by LI-COR.
MTT-assay
Cells were seeded at 30% confluence in a 48-well plate,
transduced with BIRC6 shRNA and after 24 h treated
with ZVDVAD. Seventy-two hours after treatment, 25 μl
of Thiazolyl blue tetrazolium bromide (MTT, Sigma
M2128) was added. After 4–6 h of incubation, 250 μl of
10% SDS, 0.01 M HCl was added to stop the reaction.
The absorbance was measured at 570 nm and 720 nm
using a plate-reader (Biotek).
Results
Gain of BIRC5 and BIRC6 and loss of CASP9 in
neuroblastoma tumors
To identify patterns in the aberrations of genes involved
in intrinsic apoptotic signaling, we combined high
throughput analysis of DNA copy number and mRNA
expression of these genes. We included all 31 genes that
are directly involved in the mitochondrial apoptotic path-
way and their downstream target genes (Table 1). Array
CGH data of 87 primary neuroblastoma tumor samples
were analyzed for copy number variations of the 31 genes
included in our intrinsic apoptotic gene panel. Binary
segmentation data was used to score the DNA copy
number variations and they were subsequently confirmed
using log fold data from SNP array analyses of the same
tumors. Only three genes show DNA copy number aber-
rations at a frequency above 10% (Figure 1a). The BIRC5
gene, which is located in the smallest region of overlap
(SRO) of gain of chromosomal band 17q25 [12], is gained
in 49% of the tumors. CASP9 is located at the SRO of
deletions of 1p36 [12] and it is lost in 30% of the tumors.
BIRC6, which is located on 2p22, is gained in 24% of the
neuroblastoma tumors. Distal chromosome 2p is a
known region of gain in neuroblastoma. BIRC6 is not
located in the SRO of this gained region, but is gained in
84% of the tumors with 2p gain (Figure 1b). Of these
three genes, BIRC6 was not studied before in neuroblast-
oma. We therefore investigated whether the gain of
BIRC6 resulted in aberrant expression. We compared
Figure 1 Gain of BIRC5 and BIRC6 and loss of CASP9 in neuroblastoma tumors. a: The percentage of genomic aberrations is presented on
the Y-axis and all selected genes in the intrinsic apoptotic pathway on the X-axis. Red bars indicate gained genes and green bars indicate lost
genes. When a bar is green/red combined, it means that both gains and losses in that gene occurred. The red horizontal line represents the cut-
off for further analysis. b: Chromosome 2 is represented with the regions of 2p that are gained in our dataset of 88 neuroblastoma tumors. The
BIRC6 locus is indicated with a red arrow. c: Boxplots of BIRC6 mRNA expression in tumors with or without gain of BIRC6. d: Boxplots of BIRC6
mRNA expression in 3 neuroblastoma datasets (red), adult tumors (blue) and various normal tissues (green). The boxes represent the 25th to 75th
percentile with the median depicted as a horizontal line. Extremes are indicated by the whiskers, and the presence of outliers is indicated by (o).
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gain, which shows that tumors with BIRC6 gain have sig-
nificantly higher BIRC6 RNA levels (Student T-test:
P = 3.1*10-6) (Figure 1c). Moreover, BIRC6 is also highly
expressed compared to several adult tumors and various
normal tissues (Figure 1d). These findings suggest that
the aberrant expression of BIRC6 is at least partiallycaused by genomic aberrations often occurring in neuro-
blastoma tumors.
BIRC6 knockdown induces apoptosis in neuroblastoma
cells
We investigated whether the high BIRC6 levels indeed
counteract apoptosis in neuroblastoma. We used 2
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sequence of BIRC6. SKNSH, one of the neuroblastoma
cell lines with the highest BIRC6 expression, was trans-
duced with these vectors (Figure 2a). BIRC6 is a 528 kD
protein and difficult to assess with Western blot. There-
fore we first analyzed BIRC6 protein levels by in cellFigure 2 Knockdown of BIRC6 in SKNSH induces apoptosis. a: BIRC6 m
SKNSH 48 h after transduction. The Y-axis represents the ratio between BIR
bioanalyzer. The X-axis represents the concentration BIRC6 shRNA that was
dark grey: C7 BIRC6 shRNA and light grey: C11 BIRC6 shRNA. MOI = Multip
with no virus (NV), control virus SHC002 (C) or BIRC6 shRNA (C11 and C7). B
made 72 h after transduction before protein harvest with a 100x magnitud
(SHC) or BIRC6 shRNA (C7 and C11). The dark grey bars represent cells tran
treated with BIRC6 shRNA combined with ZVDVAD, a CASP2 inhibitor. f: W
virus SHC002 (C) or BIRC6 shRNA (C11 and C7). Blots were incubated withWestern. For this method cells are fixed directly in the
culture well and stained with a BIRC6 antibody. Analysis
shows concentration dependent down-regulation of
BIRC6 protein with both BIRC6 shRNAs at 48 h after
transduction (Figure 2b). Although less optimal, we can
confirm BIRC6 down-regulation using Western blotRNA expression in 24 neuroblastoma cell lines. b: In cell western of
C6 and Actin protein expression as determined by the Odyssey
added. Black bars are cells transduced with control virus (SHC002),
licity of Infection. 2c: Western blot of SKNSH 48 h after transduction
lots were incubated with BIRC6 and actin antibodies. d: Pictures were
e. e: MTT-assay of SKNSH and IMR32 transduced with control virus
sduced with virus alone; the light grey bars represent cells that are
estern blot of SKNSH 72 h after transduction with no virus (NV), control
PARP, DIABLO and actin antibodies.
Figure 3 (See legend on next page.)
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Figure 3 DIABLO mRNA and protein expression. 3a: Boxplots of DIABLO mRNA expression in 3 neuroblastoma datasets (red), adult tumors
(blue) and various normal tissues (green). The boxes represent the 25th to 75th percentile with the median depicted as a horizontal line. Extremes
are indicated by the whiskers, and the presence of outliers is indicated by (o). 3b: Array CGH of NGP of the region of chromosome 12q24.31 in
which DIABLO is located (arrow). Both the B allele frequency (top) and the Log R ratio (bottom) are shown. The chromosome region is shown
underneath the picture. 3c: Immunofluorescence of untreated IMR32 cells. Blue is DAPI, red is mitotracker, green is DIABLO antibody. In the right
lower corner the merged pictures are shown. 3d: Cell fractionation of SJNB12 cells 24 h after addition of ABT263. The cytoplasmic fraction (cyto)
and organelle fraction (organelle) are shown. Blots were incubated with DIABLO, BCL2 and a-tubulin antibodies. 3e: Co-immunoprecipitation of
IMR32 (top) and SKNSH (bottom) with BIRC6 and DIABLO antibodies. Negative control was the immunoprecipitation antibody Flag. Also a protein
sample without antibody and for every antibody a sample without protein was used as negative control. Both blots were incubated with DIABLO
antibody. IP antibodies are indicated above the blots.
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cing induced apoptosis. Light microscopy shows a
decreased cell number and cell death at 72 h after
BIRC6 silencing (Figure 2d). This is confirmed by MTT
assays, which shows strongly reduced cell viability after
transduction with both BIRC6 shRNAs (Figure 2e, dark
grey bars). This phenotype is caused by an apoptotic re-
sponse demonstrated by PARP cleavage at 72 h after
transduction with both BIRC6 shRNAs on western blot
(Figure 2f ). These findings confirm an anti-apoptotic
role for BIRC6 in neuroblastoma cells.
High BIRC6 levels keep cytoplasmic DIABLO levels low
The BIRC6 protein functions both by silencing of DIA-
BLO and in the formation of the midbody ring during cell
division. Inhibition of each of these functions can result in
cell death. We therefore investigated which process causes
apoptosis after BIRC6 silencing in neuroblastoma. Apop-
tosis induced after inhibiting the midbody-related function
of BIRC6 has been found to be mediated by CASP2
[7,8,38]. We inhibited CASP2 by ZVDVAD, a widely used
CASP2 inhibitor [39-41] that we have previously used to
show that apoptosis induced by silencing of BIRC5 is
mediated by CASP2 [26]. ZVDVAD however does not in-
hibit apoptosis induced by BIRC6 knockdown in SKNSH
and IMR32 cells (Figure 2e). This indicates that this
process is not CASP2-mediated, implying that the role of
BIRC6 in neuroblastoma is not essential for completion of
cell division during midbody ring formation.
Alternatively, BIRC6 functions as an IAP that binds
DIABLO in the cytoplasm thereby inducing ubiquitina-
tion and degradation of DIABLO [1,2]. DIABLO mRNA
expression levels in neuroblastoma tumors are surpris-
ingly high compared to other types of tumors and com-
pared to normal tissue (Figure 3a). Moreover, we
confirm an amplification of a region on the chromosome
12q arm in the neuroblastoma cell line NGP, which
includes the DIABLO locus (Figure 3b) [42]. We there-
fore investigated whether the high BIRC6 expression
allows neuroblastoma cells to survive the high levels of
the pro-apoptotic protein DIABLO. DIABLO is a mito-
chondrial protein, which translocates to the cytoplasm
after apoptotic stimuli where it can be degraded byBIRC6. We investigated the cellular localization of DIA-
BLO and immunofluorescence indeed shows a clear
localization of DIABLO within the mitochondria
(Figure 3c), which is confirmed by cell fractionation
showing that the majority of DIABLO is localized in the
cell organelle fraction (Figure 3d). To test whether DIA-
BLO can be functionally activated upon an apoptotic
stimulus, we treated neuroblastoma cells with the BCL2
inhibitor ABT263, which results in stimulation of pore
formation in the mitochondria [43]. Cell fractionation
indicates that the cytosolic DIABLO levels increases 24
h after ABT263 treatment (Figure 3d), demonstrating
that DIABLO can be released from the mitochondria
and stimulate apoptosis.
Untreated cells have low cytoplasmic DIABLO levels
(Figure 3d). These levels are probably restricted by
BIRC6 activity. To test this hypothesis, we first investi-
gated by a co-immunoprecipitation analysis whether
BIRC6 and DIABLO physically interact in neuroblast-
oma cells. Cell lysates of SKNSH and IMR32 cells were
immunoprecipitated with a BIRC6 antibody. Western
blot analysis of these precipitates with a DIABLO anti-
body shows a strong signal at the correct position for
DIABLO. This confirms a physical interaction between
both proteins (Figure 3e). Finally, we investigated
whether silencing of BIRC6 results in increased DIABLO
protein levels. Western blot analysis of SKNSH cells
treated with two different shRNAs for BIRC6 shows that
the silencing of BIRC6 induced by both hairpins results
in a clear increase of DIABLO protein levels (Figure 2f ).
These experiments suggest that BIRC6 may effectively
inactivate cytoplasmic DIABLO in neuroblastoma cells
and can thereby prevent an apoptotic response.
Discussion and conclusions
In this paper we analyzed aberrations in gene copy num-
ber and mRNA expression of genes directly involved in
the intrinsic apoptotic pathway in neuroblastoma.
BIRC6, known as an inhibitor of the pro-apoptotic pro-
tein DIABLO, showed gene copy number gains and
increased expression. Silencing of BIRC6 with two
shRNAs targeting different parts of the coding sequence
resulted in increased cytoplasmic DIABLO levels and
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acted with DIABLO proteins.
The apoptotic response in neuroblastoma cells upon
BIRC6 silencing occurs in a background of surprisingly
high DIABLO expression levels. High cytoplasmic levels
of DIABLO can be tumor inhibitory through binding of
IAPs in the cytoplasm. We suggest two mechanisms why
high DIABLO expression does not induce apoptosis in
neuroblastoma. Firstly, we show that the major fraction
of DIABLO protein has a mitochondrial localization.
This mitochondrial sequestration is probably mediated
by the exceptionally high levels of BCL2, which occurs
in most neuroblastoma tumors [33]. Targeted inhibition
of BCL2 caused an increase in cytoplasmic DIABLO
levels, suggesting that sequestration of DIABLO in the
mitochondria occurs by inhibition of pore formation
through BCL2. Secondly, we showed that DIABLO is ef-
fectively bound by BIRC6 in neuroblastoma and that
DIABLO levels increase upon silencing of BIRC6. This
suggests an effective degradation of cytoplasmic DIA-
BLO by BIRC6. We did not find a correlation between
BIRC6 expression and prognosis or prognostic markers.
We also did not find a correlation between BIRC6 and
BCL2 or DIABLO mRNA expression (data not shown).
This can be explained by the observation that the ex-
pression of both BCL2 and DIABLO is generally high in
all neuroblastoma tumor samples and not in just a sub-
set [33]. The function of high mitochondrial DIABLO
levels in neuroblastoma remains elusive. Other pro-
apoptotic proteins in the mitochondria, like cytochrome
C, have shown to be involved in energy metabolism [44]
but no such mechanism has been found for DIABLO yet.
The interaction of BIRC6 with CASP9, which has been
reported previously [1,2,45], has not been validated in
this paper. Since CASP9 has been shown to be function-
ally active in neuroblastoma despite its location on a fre-
quently lost region [46], it would be interesting to
investigate whether there is an additional inhibition of
this protein by BIRC6 in neuroblastoma cells.
Release of the strongly increased mitochondrial
DIABLO levels would offer a therapeutic potential in
neuroblastoma. This suggests that the proteins that
impair the pro-apoptotic function of DIABLO could be
effective drug targets. The previously shown efficacy of
targeted BCL2 inhibition could relate to high DIABLO
levels [33]. Moreover, direct BIRC6 inhibition would
also increase the cytoplasmic pro-apototic function of
DIABLO. BIRC6 inhibitors are not available at this
moment, but targeted drug development might be
worth considering. BIRC6 is not located on the SRO of
2p, but it is frequently gained and functionally active
and we therefore consider BIRC6 as a potentially im-
portant player in the dysfunction of apoptosis in neuro-
blastoma. The BIRC6 gene is validated as a noveltherapeutic target. If BIRC6 inhibitors are developed, a
combined inhibition of BIRC6 and BCL2 could yield
synergistic effects.
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